I don't like to believe management has any involvement in share price suppression however the half year results are due out mid to late Feb. and this is an opportunity for them to allay concerns. At the very least they should be announcing their efforts to continue to grow Scenesse sales and demonstrate significant progress with the CUV105 Vitiligo trial. If they say nothing about this trial four months after it was started then they are actively eroding shareholder value. You cannot make a case that this information, if positive and indicative they are doing their job, should be kept away from the market. A detailed update has to be provided.
Shorts - general info, page-698
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.96 |
Change
-0.200(1.41%) |
Mkt cap ! $699.0M | |||
| Open | High | Low | Value | Volume |
| $14.20 | $14.24 | $13.88 | $631.9K | 44.90K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 416 | $13.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.04 | 192 | 1 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| CUV (ASX) Chart |